Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability

Arquivos Brasileiros de Oftalmologia

Leopoldo Magacho²  Marcelus Layguel Costa¹  André Dessimoni¹  Marcos Pereira De Ávila¹ 

[1] ,Universidade Estadual de CampinasCampinas SP ,Brasil

关键词: Dopamine Agonists;    Glaucoma;    open-angle;    Intraocular pressure;    Ophthalmic solutions;    Sensitivity and specificity;    Agonistas dopaminérgicos;    Glaucoma de ângulo aberto;    Pressão intra-ocular;    Soluções oftálmicas;    Tolerância e eficácia;    Sensibilidade e especificidade;   

DOI  :  10.1590/S0004-27492006000500015

来源: SciELO

【 摘 要 】

PURPOSE: To compare intraocular pressure (IOP) rise in normal individuals and primary open-angle glaucoma patients and the safety and efficacy of ibopamine eye drops in different concentrations as a provocative test for glaucoma. METHODS: Glaucoma patients underwent (same eye) the ibopamine provocative test with two concentrations, 1% and 2%, in a random sequence at least 3 weeks apart, but not more than 3 months. The normal individuals were randomly submitted to one of the concentrations of ibopamine (1% and 2%). The test was considered positive if there was an IOP rise greater than 3 or 4 mmHg at 30 or 45 minutes to test which subset of the test has the best sensitivity (Se)/specificity (Sp). RESULTS: There was no statistically significant difference in any of the IOP measurements, comparing 1% with 2% ibopamine. The IOP was significantly higher at 30 and 45 minutes with both concentrations (p<0.001). The best sensitivity/specificity ratio was achieved with the cutoff point set as greater than 3 mmHg at 45 minutes with 2% ibopamine (area under the ROC curve: 0.864, Se: 84.6%; Sp:73.3%). All patients described a slight burning after ibopamine's instillation. CONCLUSION: 2% ibopamine is recommended as a provocative test for glaucoma. Because both concentrations have similar ability to rise IOP, 1% ibopamine may be used to treat ocular hypotony.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License